Although primary mutations of PMS2 are uncommon, the inclusion of PMS2 immunohistochemistry may aid the identification of MLH1 germline mutations in MSI-H cancers that continue to express MLH1 (Thompson et al, 2004). This evidence concerns the gene PMS2 and cancer.